Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. SGS AG
  6. News
  7. Summary
    SGSN   CH0002497458

SGS AG

(SGSN)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 12/03 10:34:22 am
2857.5 CHF   +0.26%
10:22aSGS : Integrated Reports Release Date Announcement
PU
09:22aSGS : Annual Report Release Date Announcement
PU
11/30SGS : Lourdes Martín Appointed to EFRAG Sustainability Expert Working Group
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SGS Opens New State-of-the-Art Site for Clinical Research in Antwerp, Belgium

10/27/2021 | 04:48am EST
SGS officially opens its new clinical pharmacology research center on the Antwerp University Hospital site on October 26, 2021, in the presence of Frankie Ng, SGS CEO, to strengthen its pioneering position in the global pharmaceutical landscape.

Clinical Research News|Early Phase I-IIa

In this modern, innovative and sustainable facility, unique in Europe, SGS is contributing to the creation of a healthier and safer society.

The newly built SGS CPU, aimed at early phase research, is strategically located next to the University Hospital of Antwerp (UZA) and highlights SGS's vision to nurture and build on this existing operation. For over 40 years, SGS has been closing the gap between molecule and human, conducting complex and innovative Phase I-IIa clinical trials, where drugs are tested, often for the first time, in humans. Its proximity to UZA reinforces scientific collaboration with a network of specialists and techniques.

This was backed up by Frankie Ng, SGS CEO, who commented: "The past year and a half has shone a light on the importance of clinical research and drug development. By moving into this fantastic new facility, SGS will play a key role in shaping the future of the global pharmaceutical industry."

"Our proximity to Antwerp University Hospital means that expertise is never far away. By joining forces, we are strengthening and broadening our capabilities for early phase clinical research. This new and innovative facility positions SGS at the forefront of clinical research and helps us contribute to a healthier and safer society over the coming years," said SGS Benelux Managing Director, John Pype.

With an experienced team of experts and over 200 staff, the SGS CPU ensures smooth and efficient early phase study execution. From a database of more than 13,000 potential trial participants, the most suitable healthy people for clinical trials are selected through a variety of criteria and trials. During a stay in the SGS CPU, the safety and mechanisms of action of the potential drug are mapped. SGS CPU collaborates on clinical trials for a variety of drugs. For example, SGS CPU has recently been actively involved in several vaccine clinical trials in the fight against the COVID-19 pandemic.

This new state-of-the-art CPU is a modern, sustainable and innovative facility. With a capacity of 110 beds, unique in Europe, a wide range of settings can be provided. Study participants stay in 2 to 8-person rooms, or in individual rooms, and have access to comfortable living and leisure areas. A high-care room allows accurate follow-up during first-in-human testing of new drugs. Two specialized quarantine units are available for controlled investigation of infection models or controlled human infection models (CHIM). In recent years, the SGS CPU has conducted the first malaria challenge studies in Belgium with its own developed H3N2 (flu) virus.

In addition, the new CPU has invested heavily in innovative and sustainable technical capabilities: a Good Manufacturing Practice (GMP) production unit with clean rooms level D, C and B for sterile study drug preparations, a centrally located laboratory to facilitate complex sample processing and the use of the latest bed-side monitoring (telemetry). Environmental and sustainability issues have also been anticipated. For this, chilled and heated via climatic caps are combined with heat pumps. The roof is green and equipped with solar panels and daylight is maximized. Automated water taps and drinking fountains have been installed as well as light steering and solar blinds. Also, the outdoor environment is sustainably landscaped with flower ponds and infiltration ponds and sustainably managed.

It is clear that with a team of top experts in this state-of-the-art clinical pharmacology unit, SGS is looking to focus on the future with increasingly complex clinical trials.

"Challenge studies will continue to play a key role in the development of drug and infectious disease vaccines in the future. These studies can be a crucial time-saving step in the clinical development of antiviral drugs, for example, by showing efficiency and safety in a controlled environment quickly and safely. That is why we have also decided to focus on expanding our quarantine capacity. This will enable us to conduct studies with a wide range of study participants more efficiently and quickly," explained Annick van Riel, Director Clinical Pharmacology Unit, SGS.

In Belgium and the Netherlands, with a network of 47 offices and laboratories with 3,800 employees in various segments, SGS is a key and leading stakeholder. With over 700 employees in Belgium, clinical research and drug development is an important milestone, and the new SGS CPU marks a new milestone.

For more information, please contact:

Annick van Riel
Director SGS CPU Antwerp
t: +32 (0) 3 217 25 60
www.sgs.com

About SGS

We are SGS - the world's leading testing, inspection and certification company. We are recognized as the global benchmark for quality and integrity. Our 93,000 employees operate a network of 2,600 offices and laboratories, working together to enable a better, safer and more interconnected world.

Disclaimer

SGS SA published this content on 27 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 October 2021 08:47:05 UTC.


ę Publicnow 2021
All news about SGS AG
10:22aSGS : Integrated Reports Release Date Announcement
PU
09:22aSGS : Annual Report Release Date Announcement
PU
11/30SGS : Lourdes Martín Appointed to EFRAG Sustainability Expert Working Group
PU
11/30SGS : New Chemical Testing Lab Opens in Qingdao
PU
11/30SGS : We are a Notified Body for the EU Medical Device Regulation
PU
11/29SGS Opens Skincare Testing Lab in Hong Kong
MT
11/29SGS : New Skin Care Clinical Testing Laboratory Opens in Hong Kong
PU
11/26SGS : A New Approach to Hospitality – Hospitality Excellence
PU
11/26SGS : Mercosur Revises Food Contact Resolutions
PU
11/26SGS Buys Majority Stake In Canada-Based Sulphur Experts
MT
More news
Analyst Recommendations on SGS AG
More recommendations
Financials
Sales 2021 6 334 M 6 886 M 6 886 M
Net income 2021 641 M 697 M 697 M
Net Debt 2021 1 934 M 2 103 M 2 103 M
P/E ratio 2021 33,2x
Yield 2021 2,88%
Capitalization 21 361 M 23 226 M 23 220 M
EV / Sales 2021 3,68x
EV / Sales 2022 3,47x
Nbr of Employees 92 143
Free-Float 79,7%
Chart SGS AG
Duration : Period :
SGS AG Technical Analysis Chart | SGSN | CH0002497458 | MarketScreener
Technical analysis trends SGS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Last Close Price 2 850,00 CHF
Average target price 2 864,26 CHF
Spread / Average Target 0,50%
EPS Revisions
Managers and Directors
Frankie Ng Chief Executive Officer
Dominik de Daniel Chief Financial Officer
Calvin Grieder Chairman
Olivier Merkt Chief Compliance Officer & SVP-Legal
August Franšois von Finck Independent Director